Using magnetotactic bacteria in oncology

LETI's research will help apply magnetotactic bacteria in oncology
Credit: Saint Petersburg Electrotechnical University LETI

Kamil Gareev, Associate Professor at ETU "LETI," justified the prospects of using magnetotactic bacteria to treat malignant tumors.

LETI researchers identified the main properties of and described the possibilities of their application in medicine. The results obtained will help create theranostic agents in neurooncology and cardioprotection. The results of the joint study with colleagues from St. Petersburg State University, RAS Institute of Cytology, and RAS Institute of Biotechnology were published as an overview article in the journal Magnetochemistry.

Magnetotactic bacteria (MTB) are distinguished by their ability to synthesize magnetosomes, special cellular organelles in which magnetite biomineralization occurs. Thanks to their , MTBs and isolated magnetosomes can be used in medicine to fight cancer. Using magnetosomes, drugs can be transported directly to the malignant tumor. In addition, scientists aim to study the formation of bacterial magnetite crystals inside MTB cells, the mechanisms of magnetostatic interaction between individual magnetosomes, and their chemical and aggregative stability outside the bacterial cells. These results will become the core of research in paleomagnetism and the physics of magnetic phenomena.

LETI's research will help apply magnetotactic bacteria in oncology
Kamil Gareev, Associate Professor of the Department of Micro- and Nanoelectronics of LETI. Credit: Saint Petersburg Electrotechnical University

Currently, scientists from Germany, France, Brazil, the U.S., and Japan are engaged in large-scale research of magnetotactic bacteria. The research of LETI scientists will be the first in St. Petersburg. LETI chose an : the university formed a research team, which includes specialists in different fields—physics of magnetic phenomena, rock magnetism and magnetofossils, neurooncology, and target therapy based on nanoparticles, as well as the synthesis of composite magnetic particles based on iron oxide. That will make it possible to carry out a versatile study and obtain objective results.

"We expect to eventually complete the full cycle of research—from fermentation of MTBs in high throughput automated bioreactors of large volume and evaluation of their physical characteristics to functionalization of magnetosomes with pharmaceuticals and their laboratory tests. Thus, subject to the achievement of the set goals, for the first time in our city, there will be world-class results in this field of science," says Gareev, Associate Professor of the Department of Micro- and Nanoelectronics of LETI, Senior Researcher of the Engineering Center for Microtechnology and Diagnostics

The next stage of studying MTBs will bring scientists closer to the practical use of structures based on bacterial magnetosomes in medicine as new tools for targeted drug delivery, hyperthermia therapy, and contrast agents for magnetic resonance imaging. "Compared to currently used structures based on synthetic iron oxide nanoparticles, bacterial magnetite has better chemical stability, high uniformity in shape and size, and, even more importantly, high biocompatibility," commented Gareev.

LETI scientists obtained the first results of studying magnetic nanoparticles in 2013, and since then, research in this direction has continued. Until 2021, the research mainly focused on the properties of synthetic, rather than biogenic, magnetic nanoparticles, such as magnetosomes. The long-term experience allowed researchers to move on to a full-fledged study of magnetotactic bacteria and bacterial magnetosomes.

Explore further

Bacterial magnetic nanoparticles for biomedical applications

More information: Kamil G. Gareev et al, Magnetotactic Bacteria and Magnetosomes: Basic Properties and Applications, Magnetochemistry (2021). DOI: 10.3390/magnetochemistry7060086
Provided by Saint Petersburg Electrotechnical University LETI
Citation: Using magnetotactic bacteria in oncology (2021, July 15) retrieved 28 July 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments